Feng Liang

Feng Liang is a prominent scientist specializing in therapeutic discovery for Cystic Fibrosis, currently serving as the Group Leader of HTS and Biochemistry at the Cystic Fibrosis Foundation Therapeutics since February 2012. In this role, Feng Liang leads efforts in high-throughput screening, protein production, and various assays to support CFTR therapy development alongside industrial and academic partners. Prior experience includes positions as Principal Scientist at Flatley Discovery Lab and Scientist at FoldRx, where focus areas included Parkinson's disease and Cystic Fibrosis through the development of cell-based and biochemical assays. Previously, as Senior Scientist III at UCB Pharma, responsibilities encompassed target discovery and assay development for CNS diseases, including epilepsy and pain. Early career experience as a Cell Biologist at Valigen laid the foundation for expertise in molecular biology, complemented by a PhD from Cornell University.